# Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

> **NCT06659562** · PHASE1 · COMPLETED · sponsor: **Herantis Pharma Plc.** · enrollment: 32 (actual)

## Conditions studied

- Parkinson Disease, Idiopathic

## Interventions

- **DRUG:** HER-096
- **DRUG:** HER-096
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06659562
- **Lead sponsor:** Herantis Pharma Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-23
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659562, "Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06659562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*